Showing 1451-1460 of 2007 results for "".
- Teoxane Launches Consumer Access to Dermocosmetic Skincare Line in U.S.https://modernaesthetics.com/news/teoxane-launches-consumer-access-to-dermocosmetic-skincare-line-in-us/2475362/Teoxane has announced the U.S. launch of its dermocosmetics line, making its clinically developed skincare products available directly to consumers for the first time through its new online platform, teoxane.us. Previously offered exclusively through aesthetic professionals, the Swiss comp
- Federal Court Rules In Favor Of Permanent Injunction In InMode Counterfeit Device Casehttps://modernaesthetics.com/news/federal-court-grants-permanent-injection-to-inmode-in-counterfeit-device-case/2475361/The U.S. District Court for the Central District of California has ruled in favor of InMode Ltd., granting a default judgment against multiple DHGate sellers accused of promoting and distributing counterfeit aesthetic medical devices, the company announced in a press release. In its May 6
- BOTOX® Cosmetic Expands Support Program for Women Entrepreneurs with 2025 Confidence Projecthttps://modernaesthetics.com/news/botox-cosmetic-expands-support-program-for-women-with-2025-confidence-project/2475360/Allergan Aesthetics, an AbbVie company, has announced the return and expansion of its initiative aimed at addressing the “Confidence Gap” among women entrepreneurs. The 2025 edition of The Confidence Project: Empowering Women Entrepreneurs will support 250 founders through mentorship and business
- Allergan Aesthetics Appoints Inaugural AMI Training Center Facultyhttps://modernaesthetics.com/news/allergan-aesthetics-appoints-inaugural-ami-training-center-faculty/2475356/Allergan Aesthetics, an AbbVie company, has introduced the first faculty cohort for its new Allergan Medical Institute® (AMI) Training Centers in Orange County, CA, and Atlanta, GA. The new AMI Training Center Faculty will lead immersive educational programs designed to train and support the next
- ASLMS 2025: E. Victor Ross, MD, Talks Landscape of Fractional Laser Treatmentshttps://modernaesthetics.com/news/aslms-2025-e-victor-ross-md-talks-landscape-of-fractional-laser-treatments/2475359/At the 2025 American Society for Laser Medicine and Surgery (ASLMS) Annual Meeting in Orlando, E. Victor Ross, MD, shared insights on the evolving role of fractional lasers in dermatologic practice, highlighting both their advantages and limitations. Risk, Recovery, and Pigmentatio
- Tattoo Removal Trends Revealed in Global Analysis of Over 200,000 Individualshttps://modernaesthetics.com/news/tattoo-removal-trends-revealed-in-global-analysis-of-over-200000-individuals/2475357/Key Takeaways Individuals aged 18–39 make up two-thirds of those seeking tattoo removal, with visible areas such as forearms and hands being the most treated. Black ink remains the most commonly removed tattoo pigment. Fitzpatrick Skin Types III and
- Men’s Aesthetic Practice Announces New Chief Medical Director for San Diego Clinichttps://modernaesthetics.com/news/mens-aesthetic-practice-announces-new-chief-medical-director-for-san-diego-clinic/2475355/Lushful Aesthetics, a leader in specialized sexual health and enhancement procedures, named Dr. Carlton Thomas as chief medical director of its new clinic in San Diego. Dr. Thomas will oversee medical operations next to Lushful Aesthetics founder Chris Bustamante, DNP, NP-C. Dr. Thomas gai
- Candela Launches Dual-Wavelength Vbeam Pro for Vascular and Dermatologic Conditionshttps://modernaesthetics.com/news/candela-launches-dual-wavelength-vbeam-pro-for-vascular-and-dermatologic-conditions/2475352/Candela has introduced its latest pulsed dye laser platform, the Vbeam Pro, at the 2025 Annual Meeting of the American Society for Laser Medicine and Surgery (ASLMS) in Orlando, Florida. The new system is FDA-cleared
- Allergan Aesthetics Submits BLA for TrenibotulinumtoxinE for Glabellar Lineshttps://modernaesthetics.com/news/abbvie-submits-bla-for-trenibotulinumtoxine-for-glabellar-lines/2475351/Allergan Aesthetics, an AbbVie Company, has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for trenibotulinumtoxinE (TrenibotE), seeking approval for the treatment of moderate to severe glabellar lines. TrenibotE, a serotype E botulinum toxin
- AVAVA Receives FDA Clearance for Acne Scar Treatment on All Skin Types Using Focal Point Technologyhttps://modernaesthetics.com/news/avava-receives-fda-clearance-for-acne-scar-treatment-on-all-skin-types-using-focal-point-technology/2475350/The U.S. Food and Drug Administration (FDA) has cleared AVAVA’s Focal Point Technology™ for the treatment of acne scars, marking a significant milestone in energy-based skin therapy. The technology, developed by Boston-based AVAVA, is now indicated for acne scarring in all Fitzpatrick skin types